These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21459944)

  • 1. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Keystone EC; Papp KA; Wobeser W
    J Rheumatol; 2011 Jul; 38(7):1234-43. PubMed ID: 21459944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis.
    Murakami S; Takeno M; Kirino Y; Kobayashi M; Watanabe R; Kudo M; Ihata A; Ueda A; Ohno S; Watanuki Y; Kaneko T; Ishigatsubo Y
    Tuberculosis (Edinb); 2009 Mar; 89(2):136-41. PubMed ID: 19211305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis.
    Chen DY; Shen GH; Chen YM; Chen HH; Lin CC; Hsieh CW; Lan JL
    Int J Tuberc Lung Dis; 2011 Feb; 15(2):192-200. PubMed ID: 21219680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
    Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
    J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.
    To KW; Reino JJ; Yoo DH; Tam LS
    Respirology; 2013 Jul; 18(5):765-73. PubMed ID: 23627398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
    Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
    Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test.
    Laffitte E; Janssens JP; Roux-Lombard P; Thielen AM; Barde C; Marazza G; Panizzon RG; Saurat JH
    Br J Dermatol; 2009 Oct; 161(4):797-800. PubMed ID: 19659473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
    Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
    J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.
    Chang B; Park HY; Jeon K; Ahn JK; Cha HS; Koh EM; Kang ES; Koh WJ
    Clin Rheumatol; 2011 Dec; 30(12):1535-41. PubMed ID: 21556777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor.
    Kwakernaak AJ; Houtman PM; Weel JF; Spoorenberg JP; Jansen TL
    Clin Rheumatol; 2011 Apr; 30(4):505-10. PubMed ID: 20737179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.